LEXX
Price
$2.83
Change
-$0.04 (-1.39%)
Updated
Oct 17 closing price
12 days until earnings call
MRZM
Price
$0.05
Change
-$0.00 (-0.00%)
Updated
Sep 24 closing price
40 days until earnings call
Ad is loading...

LEXX vs MRZM

Header iconLEXX vs MRZM Comparison
Open Charts LEXX vs MRZMBanner chart's image
Lexaria Bioscience
Price$2.83
Change-$0.04 (-1.39%)
Volume$189K
CapitalizationN/A
Marizyme
Price$0.05
Change-$0.00 (-0.00%)
Volume$1K
CapitalizationN/A
View a ticker or compare two or three
LEXX vs MRZM Comparison Chart
Loading...
LEXX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
LEXX vs. MRZM commentary
Oct 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LEXX is a Sell and MRZM is a Hold.

COMPARISON
Comparison
Oct 18, 2024
Stock price -- (LEXX: $2.83 vs. MRZM: $0.04)
Brand notoriety: LEXX and MRZM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LEXX: 123% vs. MRZM: 2138%
Market capitalization -- LEXX: $47.75M vs. MRZM: $6.58M
LEXX [@Biotechnology] is valued at $47.75M. MRZM’s [@Biotechnology] market capitalization is $6.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LEXX’s FA Score shows that 0 FA rating(s) are green whileMRZM’s FA Score has 0 green FA rating(s).

  • LEXX’s FA Score: 0 green, 5 red.
  • MRZM’s FA Score: 0 green, 5 red.
According to our system of comparison, LEXX is a better buy in the long-term than MRZM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LEXX’s TA Score shows that 2 TA indicator(s) are bullish.

  • LEXX’s TA Score: 2 bullish, 6 bearish.

Price Growth

LEXX (@Biotechnology) experienced а -7.52% price change this week, while MRZM (@Biotechnology) price change was -2.78% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

LEXX is expected to report earnings on Jan 15, 2025.

MRZM is expected to report earnings on Nov 27, 2024.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LEXX($47.7M) has a higher market cap than MRZM($6.58M). LEXX YTD gains are higher at: 126.400 vs. MRZM (-65.035). LEXX has higher annual earnings (EBITDA): -4.51M vs. MRZM (-28.96M). LEXX has more cash in the bank: 8.51M vs. MRZM (5.22K). LEXX has less debt than MRZM: LEXX (143K) vs MRZM (20.5M). LEXX has higher revenues than MRZM: LEXX (411K) vs MRZM (365K).
LEXXMRZMLEXX / MRZM
Capitalization47.7M6.58M725%
EBITDA-4.51M-28.96M16%
Gain YTD126.400-65.035-194%
P/E RatioN/AN/A-
Revenue411K365K113%
Total Cash8.51M5.22K162,869%
Total Debt143K20.5M1%
FUNDAMENTALS RATINGS
LEXX vs MRZM: Fundamental Ratings
LEXX
MRZM
OUTLOOK RATING
1..100
6357
VALUATION
overvalued / fair valued / undervalued
1..100
60
Fair valued
48
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3993
P/E GROWTH RATING
1..100
10069
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MRZM's Valuation (48) in the null industry is in the same range as LEXX (60). This means that MRZM’s stock grew similarly to LEXX’s over the last 12 months.

MRZM's Profit vs Risk Rating (100) in the null industry is in the same range as LEXX (100). This means that MRZM’s stock grew similarly to LEXX’s over the last 12 months.

LEXX's SMR Rating (98) in the null industry is in the same range as MRZM (100). This means that LEXX’s stock grew similarly to MRZM’s over the last 12 months.

LEXX's Price Growth Rating (39) in the null industry is somewhat better than the same rating for MRZM (93). This means that LEXX’s stock grew somewhat faster than MRZM’s over the last 12 months.

MRZM's P/E Growth Rating (69) in the null industry is in the same range as LEXX (100). This means that MRZM’s stock grew similarly to LEXX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LEXX
RSI
ODDS (%)
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 7 days ago
89%
Declines
ODDS (%)
Bearish Trend 3 days ago
83%
BollingerBands
ODDS (%)
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
LEXX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL232.150.37
+0.16%
Apple
SPY582.350.05
+0.01%
SPDR® S&P 500® ETF Trust
TSLA220.89-0.44
-0.20%
Tesla
BTC.X67399.836000-212.882810
-0.31%
Bitcoin cryptocurrency
GME21.41-0.25
-1.15%
GameStop Corp

LEXX and

Correlation & Price change

A.I.dvisor tells us that LEXX and MIST have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LEXX and MIST's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LEXX
1D Price
Change %
LEXX100%
-1.39%
MIST - LEXX
28%
Poorly correlated
+0.68%
RGNX - LEXX
27%
Poorly correlated
-1.40%
BTAI - LEXX
27%
Poorly correlated
-1.72%
VXRT - LEXX
27%
Poorly correlated
-0.79%
MRSN - LEXX
26%
Poorly correlated
N/A
More

MRZM and

Correlation & Price change

A.I.dvisor tells us that MRZM and DARE have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MRZM and DARE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MRZM
1D Price
Change %
MRZM100%
-2.78%
DARE - MRZM
23%
Poorly correlated
+0.56%
HOOK - MRZM
22%
Poorly correlated
+6.92%
LEXX - MRZM
21%
Poorly correlated
-1.39%
TPST - MRZM
21%
Poorly correlated
+3.60%
NICXF - MRZM
16%
Poorly correlated
N/A
More